EN
中文 EN
Media Report
Home >Newsroom >Media Report
ALL
2024
2018
2017
2016
2024.10.09
CanSinoBIO Secures Further Funding from the Bill & Melinda Gates Foundation
2024.08.29
CanSinoBIO Reports Outstanding H1 2024 Performance
2024.07.26
Pharma Boardroom: Yu Xuefeng – CEO & Chairman, CanSinoBIO
2024.03.27
The Commercialization of Asia's First Meningococcal Conjugate Vaccine From CanSinoBIO Represents a Significant Breakthrough
1